THE REACH
You don't have a willpower problem. You have a loop you've never named.
It started casually, and then stopped being just a Friday thing.
It's what made an impossible week survivable, and then made a normal week feel impossible without it.
It's not shame. It's functional. It's biology.
One mechanism. Many loops. Cravings. Triggers.
Reward circuitry doesn't sort by substance. It sorts by wanting. That's why the same mechanism keeps producing effects across categories nobody was studying.
In the JAMA Psychiatry alcohol trial, participants who smoked showed greater reductions in cigarettes per day on semaglutide than placebo. A randomized trial found exenatide alongside nicotine patch improved cessation outcomes and eased withdrawal. Large observational analyses have associated GLP-1 use with roughly 14% lower cannabis use disorder risk and approximately 20–26% lower cocaine use.
The science moved. Nobody told you.
For years, cravings for substances, nicotine and cannabis use were treated as separate problems from appetite and metabolism. Then researchers noticed GLP-1 medications were quieting cravings nobody had asked them to touch.
The mechanism acts on wanting itself — GLP-1 receptors sit throughout the same reward circuitry that drives the reach for nicotine, cannabis, and other substances, not just food.
RANDOMIZED TRIAL
Participants who smoked showed greater reductions in cigarettes per day on semaglutide than placebo.
Read the study →
CLINICAL TRIAL
Exenatide alongside nicotine patch improved cessation outcomes and eased withdrawal.
Read the study →
OBSERVATIONAL ANALYSIS
GLP-1 use associated with roughly 14% lower cannabis use disorder risk and approximately 20-26% lower cocaine use.
Read the study →
WHAT LEVELHEADED DOES
Quiet the loop. Rebuild what holds after.
Recovery is a performance protocol. You deserve a life worth living. Get started today and level up your life.
